US FDA accepts Bristol Myers Squibb's (BMY) new drug application for Iberdomide in patients with relapsed or refractory multiple Myeloma; target action date of August 17th

Bristol Myers Squibb's new drug application for Iberdomide has been accepted by the FDA, marking a significant potential milestone for the company in the oncology space.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

UK DMO to sell GBP 3bln of 4.125% Treasury Gilt in 2033 on the 24th of February, via auction

Bayer (BAYN GY) to make a USD 10.5bln push to settle roundup cases, according to Bloomberg

US FDA accepts Bristol Myers Squibb's (BMY) new drug application for Iberdomide in patients with relapsed or refractory multiple Myeloma; target action date of August 17th

US President Trump to visit Georgia state to spotlight economy and affordability

Amazon's (AMZN) AWS announces up to USD 100mln in Federal credits to accelerates innovation for national security and scientific mission

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

The upcoming target action date of August 17th will be critical, as approval could drive future revenue growth and positively impact stock performance, especially if market expectations shift favorably as a result.

Related headlines

The whole workspace, free to try.

Try it free